Eli Lilly's Olumiant Becomes First FDA Approved Immunomodulatory Treatment For COVID-19

The FDA approved Eli Lilly And Co's LLY Olumiant (baricitinib) for COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval.
The FDA first issued an emergency use authorization (EUA) for Olumiant combined with remdesivir to treat COVID-19 in hospitalized adults and pediatric patients in November 2020.
Related: Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance.
In July 2021, the FDA revised the EUA to authorize Olumiant as a standalone treatment.
Olumiant remains under EUA status for hospitalized pediatric patients 2 to less than 18 years of age requiring supplemental oxygen, mechanical ventilation, or ECMO.
The FDA has revised the Letter of Authorization and associated fact sheets to remove the population covered under the approved indication.
Price Action: LLY shares closed 0.08% higher at $285.70 during after-hours trading on Tuesday.

Overview Rating:

Speculative

0100